

Clinical trials of VKA

TrialResults-center www.trialresultscenter.org

1 venous thrombosis

Trial	Treatments	Patients	Trials design and methods
VKA vs control			
AUREC FVII , 2009 n=17/17 follow-up: 37 months mean	continue VKA for additional 24 months versus discontinuation	patients with first spontaneous VTE and FVIII levels >230 IU/dl after 6 monthsh of VKA	
DACUS (Siragusa) , 2008 [NCT00438230] n=88/92 follow-up:	anticoagulants for 9 additional months versus no treatment	with a first episode of deep vein thrombosis, treated with OAT for 3 months and with Residual vein thrombosis	
DURAC II , 1997 n=116/111 follow-up: 4 years	anticoagulant therapy continued indefinitely versus six months of oral anticoagulant therapy	patients who had had a second episode of venous thromboembolism	
PROLONG (Palarati) , 2006 [NCT00264277] n=105/122 follow-up: 1.4 years	resume treatment versus discontinue treatment	patients with a first unprovoked proximal deep-vein thrombosis or pulmonary embolism who had received a vitamin K antagonist for at least 3 months and with abnormal D-dimer testing 1 month after the discontinuation of anticoagulation	
WODIT DVT , 2001 n=134/133 follow-up: at least two years	continuation for nine additional months versus discontinuation	Patients with a first episode of idiopathic proximal deep venous thrombosis who had completed three months of oral anticoagulant therapy	
WODIT PE , 2003 n=165/161 follow-up:	-	patients after a first episode of pulmonary embolismwho had had 3 months of oral anticoagulant therapy without experiencing recurrence or bleeding	
DDOAT2006 ongoing [NCT00895505] n=300 follow-up: 24 months	Extension of OAT versus discontinuation	-	
VKA vs placebo			

continued...

Trial	Treatments	Patients	Trials design and methods
PADIS-PE (Couturaud) , 2015 [NCT00740883] n=184/187 follow-up:	additional 18-month treatment with warfarin versus placebo	patients who had experienced a first episode of symptomatic unprovoked pulmonary embolism (ie, with no major risk factor for thrombosis) and had been treated initially for 6 uninterrupted months with a vitamin K antagonist	double-blind

More details and results :

- antithrombotics for venous thrombosis in secondary prevention - 2 at <http://www.trialresultscenter.org/go-Q682>

References

AUREC FVII, 2009:

Eischer L, Gartner V, Schulman S, Kyrle PA, Eichinger S 6 versus 30 months anticoagulation for recurrent venous thrombosis in patients with high factor VIII. *Ann Hematol* 2009;88:485-90 [18931845] [10.1007/s00277-008-0626-1](https://doi.org/10.1007/s00277-008-0626-1)

DACUS (Siragusa), 2008:

Siragusa S, Malato A, Anastasio R, Cigna V, Milio G, Amato C, Bellisi M, Attanzio MT, Cormaci O, Pellegrino M, Dolce A, Casuccio A, Bajardi G, Mariani G Residual vein thrombosis to establish duration of anticoagulation after a first episode of deep vein thrombosis: the Duration of Anticoagulation based on Compression UltraSonography (DACUS) study. *Blood* 2008;112:511-5 [18497320] [10.1182/blood-2008-01-131656](https://doi.org/10.1182/blood-2008-01-131656)

DURAC II, 1997:

Schulman S, Granqvist S, Holmström M, Carlsson A, Lindmarker P, Nicol P, Eklund SG, Nordlander S, Lrfars G, Leijd B, Linder O, Loogna E The duration of oral anticoagulant therapy after a second episode of venous thromboembolism. The Duration of Anticoagulation Trial Study Group. *N Engl J Med* 1997;336:393-8 [9010144] [10.1056/NEJM199702063360601](https://doi.org/10.1056/NEJM199702063360601)

PROLONG (Palarati), 2006:

Palareti G, Cosmi B, Legnani C, Tosetto A, Brusi C, Iorio A, Pengo V, Ghirarduzzi A, Pattacini C, Testa S, Lensing AW, Tripodi A D-dimer testing to determine the duration of anticoagulation therapy. *N Engl J Med* 2006;355:1780-9 [17065639]

WODIT DVT, 2001:

Agnelli G, Prandoni P, Santamaria MG, Bagatella P, Iorio A, Bazzan M, Moia M, Guazzaloca G, Bertoldi A, Tomasi C, Scannapieco G, Ageno W Three months versus one year of oral anticoagulant therapy for idiopathic deep venous thrombosis. Warfarin Optimal Duration Italian Trial Investigators. *N Engl J Med* 2001;345:165-9 [11463010] [10.1056/NEJM200107193450302](https://doi.org/10.1056/NEJM200107193450302)

WODIT PE, 2003:

Agnelli G, Prandoni P, Becattini C, Silingardi M, Taliani MR, Miccio M, Imberti D, Poggio R, Ageno W, Pogliani E, Porro F, Zonzin P Extended oral anticoagulant therapy after a first episode of pulmonary embolism. *Ann Intern Med* 2003;139:19-25 [12834314]

DDOAT2006, :

ongoing trial NCT00895505

PADIS-PE (Couturaud), 2015:

Couturaud F, Sanchez O, Pernod G, Mismetti P, Jago P, Duhamel E, Provost K, dit Sollier CB, Presles E, Castellant P, Parent F, Salaun PY, Bressollette L, Nonent M, Lorillon P, Girard P, Lacut K, Gagan M, Bosson JL, Laporte S, Leroyer C, Dcousus H, Meyer Six Months vs Extended Oral Anticoagulation After a First Episode of Pulmonary Embolism: The PADIS-PE Randomized Clinical Trial. JAMA 2015;314:31-40 [[26151264](#)] [10.1001/jama.2015.7046](#)